About T1D Fund
T1D Fund is a venture capital firm founded in 2016. It is primarily based out of Boston, United States. As of Oct 2026, T1D Fund is an active investor, having invested in 39 companies, with 4 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of Matchpoint Therapeutics Overall, T1D Fund portfolio has seen 3 IPOs and 8 acquisitions including key companies like Century Therapeutics, Immunocore and VTV Therapeutics. A lot of funds co-invest with T1D Fund, with names like Sanofi Ventures sharing a substantial percentage of its portfolio. T1D Fund has team of 21 people including 10 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
T1D Fund's List of Top Investments
T1D Fund has a portfolio of 39 companies. Their most notable investments are in Jaguar Gene Therapy and Zag Bio.Their portfolio spans across United States, Canada, France and 4 more locations. They have invested in Life Sciences, High Tech, HealthTech and 2 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by T1D Fund:Developer of bioprinting technology and tissue therapeutics for regenerative medicine. The company’s platform integrates bioprinting, computational design, therapeutic cells, and biomaterials. It develops implantable tissues to replace, repair, or supplement biological functions. The focus is on creating solutions for metabolic and endocrine diseases. The company also collaborates with other organizations.
Key facts about Aspect Biosystems
- Founded Year: 2013
- Location: Vancouver (Canada)
- Stage: Series B
- Total Funding till date: $139M
- Employee Count: 148 as on Sep 30, 2026
- Investors: Rising Tide Fund, Pangaea Ventures and 21 Others
- Latest Funding Round: Series B, Jan 08, 2025, $*****
- Highlight: Editors' Pick
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
Key facts about Century Therapeutics
- Founded Year: 2018
- Location: Philadelphia (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $410M
- Employee Count: 119 as on Aug 31, 2026
- Investors: Bain Capital Life Sciences, Venrock and 22 Others
- Latest Funding Round: Post IPO, Jan 08, 2026, $*****
- Highlight: Public
3. eGenesis
Developer of a gene transplantation platform for humanizing pig cells. The company has developed a technology to humanize pig cells that will grow into human-compatible organs. These organs will be harvested in the donor pig and safely transplanted to human patients. The company's technology is based on the next-generation genome engineering toolset and CRISPR.
Key facts about eGenesis
- Founded Year: 2015
- Location: Cambridge (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $495M
- Employee Count: 153 as on Sep 30, 2026
- Investors: SymBiosis, Monashee Investment Management and 31 Others
- Latest Funding Round: Series D, Aug 25, 2026, $*****
- Highlight: Editors' Pick
4. Immunocore
Developer of bispecific T cell receptor therapies for human diseases. These therapeutic agents utilize modular technology to modulate immune system activity. The mechanism involves targeting diseased cells to facilitate immune recognition and destruction or reducing immune responses in autoimmune conditions. The research and development focus includes applications for solid tumors, infectious diseases, and autoimmune disorders.
Key facts about Immunocore
- Founded Year: 2008
- Location: Abingdon (United Kingdom)
- Stage: Public
- Total Funding till date: $601M
- Employee Count: 609 as on Sep 30, 2026
- Investors: HTIF, RTW Investments and 50 Others
- Latest Funding Round: Post IPO, Jul 18, 2022, $*****
- Highlight: Public
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Key facts about Kriya Therapeutics
- Founded Year: 2012
- Location: Redwood City (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $938M
- Employee Count: 4 as on Sep 30, 2026
- Investors: Foresite Capital, CAM Capital and 16 Others
- Latest Funding Round: Series D, Jul 31, 2025, $*****
- Highlight: Editors' Pick
T1D Fund's Year-on-Year Investment Trends
T1D Fund has invested in 39 companies over the last 10 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 4 investments, while as of Oct 2026, it has made 3 investments in this year. Its most recent first time investment was in Matchpoint Therapeutics and most recent follow-on round was in Kriya Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 0 | 3 |
2025 | 3 | 1 | 4 |
2024 | 3 | 0 | 3 |
2023 | 0 | 3 | 3 |
2022 | 2 | 2 | 4 |
2021 | 4 | 4 | 8 |
2020 | 5 | 4 | 9 |
2019 | 4 | 1 | 5 |
2018 | 4 | 1 | 5 |
2017 | 6 | 1 | 7 |
T1D Fund's Investments by Stage
T1D Fund has made 15 investments in Series A stage with an average round size of $46.6M, 8 investments in Series B stage with an average round size of $75.3M and 6 investments in Seed stage with an average round size of $5.81M.Stage of entry | No. of Investments |
|---|---|
Series A | 15 |
Series B | 8 |
Seed | 6 |
Series C | 4 |
Post IPO | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
T1D Fund's Investments by Sector
T1D Fund has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Internet of Things - Industry Applications and Healthcare. Notably, it has invested in 38 Tech companies, 35 Enterprise (B2B) companies, 6 Tech hardware companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 34 |
High Tech | 8 |
HealthTech | 4 |
Internet of Things - Industry Applications | 2 |
Healthcare | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
T1D Fund's Investments by Geography
T1D Fund has made most investments in United States (28), followed by Canada where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 28 |
Canada | 3 |
France | 1 |
Israel | 1 |
Italy | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
T1D Fund's recent investments
T1D Fund has made 3 investments in 2026 so far. Matchpoint Therapeutics and CASPIAN THERAPEUTICS are the latest among them.Here are the most recent investments by T1D Fund:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 07, 2026 | United States | Series B | 7655 | [+8] | |
Sep 08, 2026 | United States | Series C | 7507 | [+3] | |
Jan 08, 2026 | United States | Post IPO | 3599 | [+5] | |
Oct 28, 2025 | United States | Series A | 9383 | [+8] | |
Jul 31, 2025 | United States | Series D | 6825 |
IPOs and Publicly Listed companies in T1D Fund's Portfolio
3 of T1D Fund's portfolio companies have become public. Century Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2021 at marketcap of $1.1B and Immunocore got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.1B.Here are T1D Fund's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 18, 2021 | Jan 08, 2026 | Post IPO | 8551 | |
Feb 05, 2021 | Apr 10, 2019 | Series B | 9112 | |
Jul 30, 2015 | Feb 28, 2024 | Post IPO | 6155 |
Acquired companies in T1D Fund's Portfolio
8 companies from T1D Fund's portfolio have been acquired. The most recent acquisition was SQZBiotech in Feb 2024 by Stem Cell Technologies for $*****.Here are T1D Fund's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 29, 2024 | Dec 05, 2017 | Series B | 6351 | |
Sep 05, 2023 | Oct 18, 2016 | Series A | 6367 | |
Mar 13, 2023 | May 04, 2017 | Series A | 4042 | |
Jul 21, 2022 | - | - | 4491 | |
Sep 13, 2021 | Apr 27, 2017 | Series A | 6326 |
Team profile of T1D Fund
T1D Fund has a team of 21 members including 10 Partners and 1 Principal located in United States. T1D Fund's team does not sit on the board of any company as of now.Here is a list of top team members in T1D Fund:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | ||
Partner | Cambridge | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | - | - | ||
Principal | New York City | - |
Co-investors of T1D Fund
Over the past 10 years, 286 investors have co-invested in T1D Fund's portfolio companies. This includes funds and angels.
- Invested before T1D Fund: HHS, Arch Venture Partners and 109 others have invested in rounds before T1D Fund. There are 5 companies where HHS has invested before T1D Fund and 4 companies where Arch Venture Partners has invested before T1D Fund.
- Top Co-investors of T1D Fund: 77 investors entered a company along with T1D Fund. These include investors like Sanofi Ventures (3 companies).
- Invested after T1D Fund: A total of 98 investors have invested in T1D Fund's portfolio after their investments. Top Investors include Hatteras Venture Partners (2 companies), Alexandria (2 companies) and Google Ventures (2 companies).
Recent News related to T1D Fund
•
Matchpoint Therapeutics Secures $150M Series B FundingMassinvestor•Oct 08, 2026•Nextech Invest, Invus, T1D Fund, BB Biotech and 5 others
•
T1D Fund Appoints Entrepreneur, Philanthropist and Bukhman Foundation Co-Founder Anastasia Bukhman to Board of DirectorsBusiness Wire•Apr 09, 2026•T1D Fund
•
Zag Bio launches with $80M to train the immune system for better TregsEndpoints•Oct 28, 2025•T1D Fund, Polaris Partners, Zag Bio, Regeneron Ventures and 7 others
•
AP Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene TherapiesBakersfield•Sep 10, 2025•Premji Invest, Patient Square Capital, Kriya Therapeutics, Narya and 1 other
•
•
SAB BIO Announces Oversubscribed $175 Million Private PlacementGlobeNewswire•Jul 21, 2025•Sanofi, RA Capital Management, Commodore Capital, Vivo Capital and 10 others
•
Zucara Therapeutics Raises $5M in Series B FinancingFinSMEs•May 01, 2025•Zucara Therapeutics, T1D Fund, Xontogeny
•
Aspect Biosystems raises US$115m Series BAngel News•Jan 17, 2025•Aspect Biosystems, New Nordic, Radical Ventures, InBC and 10 others
•
T1D Fund names industry veteran CEO to fast-track Type 1 diabetes cures via impact investing.PR Newswire•Jan 08, 2025•T1D Fund
•
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue TherapeuticsBusiness Wire•Jan 08, 2025•Aspect Biosystems, InBC, Pallasite Ventures, Pangaea Ventures and 6 others
